Actemra SC TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: tocilizumab
Brand name
(ARTG)
: ACTEMRA SC tocilizumab (rch) 162 mg/0.9 mL solution for injection pre-filled syringeDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
Rheumatoid Arthritis (IV and SC formulations),Actemra is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients in combination with methotrexate (MTX) or other non-biological disease-modifying anti-rheumatic drugs (DMARDs) in case of either an inadequate response or intolerance to previous therapy with one or more DMARDs.,Actemra is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients with poor prognostic factors (see section 5.1 Pharmacodynamic Properties, Clinical Trials) in combination with MTX in those not previously treated with MTX.,In the two groups of patients above, Actemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.,Actemra has been shown to inhibit the progression of joint damage in adults, as measured by X-ray, when given in combination with methotrexate.,Giant Cell Arteritis (SC formulations only),Actemra is indicated for the treatment of giant cell arteritis (GCA) in adult patients.,Polyarticular Juvenile Idiopathic Arthritis (IV and SC formulations),Actemra is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to or intolerance to methotrexate (MTX). Actemra can be given alone or in combination with MTX.,Systemic Juvenile Idiopathic Arthritis (IV and SC formulations),Intravenous formulation,Actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.,Subcutaneous formulation,Actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 1 year of age and older.,Actemra IV and SC can be given alone or in combination with methotrexate (MTX).
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Subcutaneous
- Clear to strongly opalescent, colourless to slightly yellowish solution
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Refrigerate
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 syringe pack
- 4 syringes pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient tocilizumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
